EN DE
Watch Prelude Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Prelude Therapeutics Inc (PRLD) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Prelude Therapeutics Inc stock $2.58, price $3.41, that is 24.3% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US74065P1012

PT Prelude Therapeutics Inc logo Thin data Nov 15, 2026

Prelude Therapeutics Inc

PRLD · US

Expensive (fair value 24% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Revenue last quarter +41% vs. a year ago. 
Mixed Growth (revenue YoY +73.4 %/yr in USD) 
Fair value $2.58 · Overvalued 
Quality 34/100 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Prelude Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$38.65 $0.6105 Fair Value $2.58 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $0.6105 – $38.65 · fair‑value band $1.94 – $3.23 · the $3.41 price screens above the $2.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Prelude Therapeutics in your weekly email

Every Wednesday you see whether Prelude Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Show moreShow less

It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.

Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Stock analysis

Prelude Therapeutics Inc (PRLD) currently trades at $3.41, while our estimate is $2.58, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.94 (bear) to $3.23 (bull), the price of $3.41 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Prelude Therapeutics Inc reported revenue of $12.1M in FY2025 versus $0 in FY2021. Reported net income was −$99.5M in FY2025.

Key figures

Market cap $336M Small · P/S ratio 12.3 · EPS (TTM) $−0.7300 · Return on equity −57.7% · Return on assets (EBIT) −58.9% (5-year average) · Operating margin −295% · Revenue (TTM) $22.4M · Revenue growth (YoY) +41.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 154% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, PRLD screens richer than that median.

Fair Value

Bear $1.94 Fair Value $2.58 Bull $3.23
Price $3.41 · Downside -24.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyOrbiMed Genesis GP LLCDirector, 10% owner2,815,315 shares at $4.44$12.5MApr 21, 2026
  • BuyDavid P BonitaDirector, 10% owner2,815,315 shares at $4.44$12.5MApr 21, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PRLD screens overvalued: fair value 24% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Prelude Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −24.3% · Below median
Profitability
Return on assets −70.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 41.0% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.89× · Pricier than median
P/S (12 months) 14.96× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)1 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs PRLD
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs PRLD
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs PRLD
argenx SE ARGX $950.95 $908.40 −4% vs PRLD
CSL Limited CSL A$199.55 A$186.49 −7% vs PRLD
Moderna, Inc MRNA $215.27 $135.64 −37% vs PRLD
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs PRLD
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs PRLD
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs PRLD
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs PRLD

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prelude Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Prelude Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/PRLD

Frequently asked questions

Is Prelude Therapeutics Inc (PRLD) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $2.58 versus a price of $3.41, about 24% lower (overvalued).
What is the fair value of PRLD?
Our estimate for Prelude Therapeutics Inc is $2.58 (as of Nov 15, 2026), built from audited fundamentals. The current price: $3.41.
What is the quality score of PRLD?
Prelude Therapeutics Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prelude Therapeutics Inc (PRLD)?
Our calculated price target is the estimate of $2.58 (as of Nov 15, 2026). Cautious scenario $1.94, optimistic scenario $3.23. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Prelude Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $2.58, about 24% lower versus a price of $3.41 (overvalued). Cautious scenario $1.94, optimistic scenario $3.23. The calculation is refreshed regularly with new filings.
What is the revenue of Prelude Therapeutics Inc (PRLD)?
Prelude Therapeutics Inc reported trailing-twelve-month revenue of about $22.4M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Prelude Therapeutics Inc (PRLD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prelude Therapeutics Inc it is $2.58 per share (as of Nov 15, 2026), against a price of $3.41.
Is Prelude Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, PRLD trades above its calculated fair value: price $3.41, fair value $2.58, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRLD?
No. The price is what the market pays today ($3.41); the fair value is what the company's own numbers justify ($2.58). For Prelude Therapeutics Inc the two are $0.8300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prelude Therapeutics Inc worth?
The market values Prelude Therapeutics Inc at about $336M (market capitalisation, as of Nov 15, 2026). Per share that is $3.41; our models calculate a fair value of $2.58 per share.
What do the bullish and bearish scenarios say about PRLD?
Our models span a range for Prelude Therapeutics Inc: cautious scenario $1.94, base $2.58, optimistic $3.23 per share (as of Nov 15, 2026, price $3.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Prelude Therapeutics Inc (PRLD)?
Balance-sheet figures for Prelude Therapeutics Inc (as of Nov 15, 2026): return on equity −57.7%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is PRLD from its 52-week high?
Prelude Therapeutics Inc trades at $3.41, about 49% below its 52-week high of $6.63 and 154% above the low of $1.35 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $2.58 is for.
Which stocks are comparable to Prelude Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prelude Therapeutics Inc stock attractive at the current price?
The data as of Nov 15, 2026: price $3.41, calculated fair value $2.58 (−24%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Prelude Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prelude Therapeutics Inc (PRLD)?
The closing price on Nov 16, 2026 was $3.41. Our estimate is $2.58, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prelude Therapeutics Inc right now?
The price sits above even our optimistic bull case ($3.23). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Prelude Therapeutics Inc

How large is the market capitalisation of Prelude Therapeutics Inc (PRLD)?
The market capitalisation of Prelude Therapeutics Inc is $336M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prelude Therapeutics Inc (PRLD)?
The price-to-sales ratio of Prelude Therapeutics Inc is 12.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prelude Therapeutics Inc (PRLD)?
Earnings per share at Prelude Therapeutics Inc are $−0.7300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Prelude Therapeutics Inc (PRLD)?
The return on equity (ROE) of Prelude Therapeutics Inc is −57.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prelude Therapeutics Inc (PRLD)?
On an EBIT basis the return on assets of Prelude Therapeutics Inc is −58.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prelude Therapeutics Inc (PRLD)?
The operating margin of Prelude Therapeutics Inc is −295% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prelude Therapeutics Inc (PRLD)?
Revenue at Prelude Therapeutics Inc is growing 41.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prelude Therapeutics Inc (PRLD) generate?
The free cash flow of Prelude Therapeutics Inc is −$56.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Prelude Therapeutics Inc (PRLD) hold?
Prelude Therapeutics Inc holds more cash than debt, $17.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Prelude Therapeutics Inc in the live analysis

One click puts Prelude Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.